🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesEchocardiographic changes on GLP-1 — November 2025 Page 2

Echocardiographic changes on GLP-1 — November 2025

NeuroNate Sat, Mar 14, 2026 at 8:34 PM 29 replies 1,138 viewsPage 2 of 6
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Mar 14, 2026 at 11:05 PM#6
Dr.CardioMD said:
I want to bring up the cardiovascular angle on cardiovascular risk.

I read this differently from Dr.CardioMD, on substance rather than tone. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

Last edited: Mar 15, 2026 at 5:05 AM
41 19anna.melb_AU, mark_tokyo, hans_munich and 38 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Mar 15, 2026 at 12:04 AM#7
NeuroNate said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

6 month update on cardiovascular risk: down 53 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.

Last edited: Mar 15, 2026 at 3:04 AM
42 20AmyNC_wife, SkepticalSean, Dr.CardioMD and 39 others
Reply Quote Save Share Report
DebRD_ATL
Senior Member
1,678
7,890
Feb 2024
Atlanta, GA
Mar 15, 2026 at 1:03 AM#8
julia.endo said:
The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

43 21SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 40 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.NephBHM_UK
Member
456
2,123
Jun 2024
Birmingham, UK
Mar 15, 2026 at 2:02 AM#9

One thing that is still open after rachel_ABQ’s answer:

What did you change at the same time, and can you separate the two now?

44 22SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 41 others
Reply Quote Save Share Report
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Mar 15, 2026 at 6:45 AM#10
DebRD_ATL said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
Last edited: Mar 15, 2026 at 12:45 PM
34 7Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 31 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register